Prostate cancer: the American Cancer Society now recommends a PSA test every two years for men aged 50 to 69 (and from 45 for some)
The American Cancer Society published an updated guideline on November 12: for the first time it directly recommends the PSA test, a simple blood test, every two years for average-risk men aged 50 to 69, and every year from 45 for those at higher risk.
Photo: SELF Magazine / Wikimedia Commons · CC BY 2.0
An older man receives care at a medical appointment; he is not a person in this story. Reference photo: SELF Magazine / Wikimedia Commons (CC BY 2.0).
Until now, the American Cancer Society (ACS) left it up to each man, together with his doctor, to decide whether or not to be tested for prostate cancer. That changed on November 12: the organization published an updated guideline that, for the first time, directly recommends regular testing with the prostate-specific antigen (PSA) test, a blood test.
The change may sound technical, but it affects millions of men.
What the new guideline says, by age
According to the ACS's official statement, the main recommendations are:
- Average risk, ages 50 to 69: a PSA test every two years.
- Higher risk (Black men and men with a strong family history, for example a father or brother diagnosed before 65, or several first-degree relatives): PSA every year from age 45 to 69.
- Men with a single first-degree relative diagnosed at 65 or older: every two years, from 45.
- Ages 70 to 74: an individual decision with the doctor, because the balance of benefits and risks is uncertain.
- From age 75: routine screening is not recommended (with some exceptions to discuss with the doctor between 75 and 79), and it is not recommended from 80 or when life expectancy is ten years or less.
A high PSA does not mean cancer
The guideline stresses a point that reassures many: a high value is not a diagnosis. The ACS considers a PSA of 3.0 ng/mL or more high between ages 45 and 69, and 6.5 ng/mL or more between 70 and 74. In that case, it recommends repeating the test between two weeks and three months later, because other conditions can raise it.
If the high value is confirmed, the recommendation is to offer a prostate MRI or a validated biomarker before deciding on a biopsy. And tumors that appear low-risk can be followed with active surveillance instead of being treated right away, AP reported.
Why the recommendation changed
The ACS explains that there is now stronger evidence that PSA screening reduces the risk of an advanced diagnosis and of dying from the disease, and that newer strategies (repeat testing, MRI, active surveillance) reduce the harms that used to be a concern, such as unnecessary biopsies and treatments.
According to AP, in 2023 fewer than 40% of men in that age group in the United States had a PSA test. The guideline does not recommend the digital rectal exam as the primary screening method.
Keep in mind that this is a US guideline: official recommendations may differ in each country. What matters is not leaving it for "someday." Talk to your doctor about when you should start, especially if your father or a brother had prostate cancer.
Read also: Noviembre Azul: a qué edad hablar con el médico sobre la próstata · Infertilidad masculina: las claves que pocos conocen
Sources
For information only. It does not replace advice from a health professional. Medical disclaimer